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Methods and Materials: Data of patients with EEC who were 
treated with RBT alone was extracted from a prospective 
database of patients with esophageal cancer treated between 
2008- 15. Demographic, tumour, treatment and outcomes data 
were analyzed. Under direct endoscopic visualization, the 
cranial and caudal extent of the tumour was recorded using 
fluoroscopic imaging. A 4 mm intra-esophageal catheter with a 
marker wire was passed across a guide wire placed under 
endoscopic vision across the tumour into the stomach. Following 
catheter visualization and positioning fluoroscopically, a 
treatment length included the tumour with a 4 cm margin 
craniocaudally. Dose was prescribed at 1 cm from the centre of 
the source axis and was delivered with 192- Ir Varisource HDR 
afterloader. Patients received 24 Gy/4 fractions over two weeks. 
Patients were followed with CT scan and upper GI endoscopy; 
biopsies were taken if there were suspicious findings. Actuarial 
overall (OS), cancer-specific survival (CSS), disease-free survival 
(DFS) were calculated using Kaplan-Meier analyses. 
Results: Twelve patients with EEC treated with RBT alone were 
included in the analysis. Among these patients, 11 patients were 
deemed not candidate for S and/or CRT due to their 
comorbidities and one patient refused S/CRT. Median follow up 
was 11 months (range 3-70 months). Median age was 81 years 
(range 56 - 91 years) and median Charlson-comorbidity index was 
6. They had T1-3N0M0 adenocarcinomas (n = 7), squamous cell 
carcinomas (n = 4) or poorly differentiated carcinoma (n = 1). 
Tumour location included Upper thoracic (n = 2), lower thoracic 
(n = 5) and GEJ (n = 5). Median treatment length was 13 cm 
(range 8 - 17 cm). Two patients had local recurrence and died 
from their cancer; three patients died from non-cancer-related 
causes. No significant acute toxicities (e.g. perforations, severe 
esophagitis, bleeding) were recorded. Both the three- and five-
year OS were 50%: three- and five-year CSS 76%: both three- and 
five-year DFS = 76%. Long-term complications included 
esophageal strictures (n = 3; median time to stricture 4.8 (3.5 - 
16 months) that needed dilations and chronic esophageal ulcer 
that healed after 14 months (n = 1). No patient developed a 
fistula. 
Conclusions: In this series of patients unsuited for S, CRT or EMR 
due to comorbidities/ tumour extension/ patient refusal to S or 
CRT, RBT alone was a safe and effective treatment modality for 
EEC. This is one of the largest North American series of EEC 
treated with RBT alone. 
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Purpose: The present study aimed to perform a direct 
comparison of several existing risk stratification tools for 
localized prostate cancer in two large databases using a variety 
of statistical techniques to quantify their ability to predict for 
biochemical failure. 
Methods and Materials: Patients who were treated with external 
beam radiotherapy (EBRT) or brachytherapy for localized 
prostate cancer were selected from a multicentre database (n = 
7974) and a validation database (n = 2266). The primary outcome 
was biochemical failure-free survival (BFFS) using the ASTRO 
“Phoenix” definition. Net reclassification index (NRI), 
concordance index (C-index) and decision curve analysis (DCA) 
were used to predict BFFS and overall survival. 
Results: NRI and C-index identified the Prostate Cancer Risk 
Stratification (ProCaRS) , Cancer of the Prostate Risk Assessment 
(CAPRA) 10-point and 3-point as superior to the Genitourinary 
Radiation Oncologists of Canada (GUROC) and National 
Comprehensive Cancer Network (NCCN) risk stratification 
systems. C-indices for CAPRA (10-point), CAPRA (3 category) and 
ProCaRS were 0.72, 0.70 and 0.71 for multicentre database and 
0.66, 0.64, 0.63 for the validation database respectively. 
However, many of these comparisons were not found to be 
significant. DCA identified minimal differences across the 
different risk stratification systems with no system emerging 
with optimal net benefit. 
Conclusions: A direct comparison between existing risk 
stratification tools, using a variety of statistical techniques, 
demonstrated minimal clinically significant differences in 
discriminative ability between the various tools with the CAPRA 
and ProCaRS systems performing best. This study highlights the 
limitations of current risk stratification tools. The incorporation 
of novel prognostic variables such as genomic markers is needed 




A MULTICENTRE MIXED-METHODS EVALUATION OF THE EXPANDED 
PROSTATE CANCER INDEX COMPOSITE FOR CLINICAL PRACTICE 
(EPIC-CP) AS A PATIENT-REPORTED ASSESSMENT TOOL IN MEN 
WITH EARLY-STAGE PROSTATE CANCER 
Michael Brundage1, Doris Howell2, Sarah Stevens3, Farzana Haji3, 
Zahra Ismail3, Maria Rugg4, Colleen Graham5, Alyssa Macedo2, 
Tracie Hanna1, Andrew Matthew2 
1Cancer Centre of Southern Ontario, Queen’s University, 
Kingston, ON 
2Princess Margaret Cancer Centre, Toronto, ON 
3CancerCare Ontario, Toronto, ON 
4Carlo Fidani Regional Cancer Program, Peel, ON 
5Waterloo Wellington Regional Cancer Program, Waterloo, ON  
 
Purpose: Patient reported outcomes (PROs) can enhance person-
centred care. Clinical use of the Edmonton Symptom Assessment 
Scale (ESAS-R) is a standard of care in Ontario cancer centres, 
but evidence from clinician surveys illustrates that ESAS-R has 
limited value in men with localized prostate cancer as it does not 
address symptoms most relevant to the prostate cancer patient 
population. The Expanded Prostate Cancer Index Composite for 
Clinical Practice (EPIC-CP) has been validated as a PRO designed 
for use in enhancing the patient encounter in the care of men 
with prostate cancer. We undertook a systematic evaluation of 
EPIC-CP (used in addition to ESAS-R) in four Ontario cancer 
centres.  
Methods and Materials: Prostate cancer patients were recruited 
from four centres over eight months (to June 2015). Eligible 
patients were those attending radiation or surgical consultation, 
follow up, or on-treatment review clinics. Consenting patients 
completed the EPIC-CP tool on a tablet. The resultant scores 
were graphically summarized and made available to the 
nurse/physician at the clinical encounter. Evaluations of EPIC-CP 
from the patients’ perspectives were obtained quantitatively by 
use of a nine-item questionnaire completed by each patient post-
encounter. Providers’ perspectives were obtained through 
thematic content analysis of one-on-one semi-structured 
interviews with participating clinicians. 
Results: Overall, 287 Patients completed an average of 3 EPIC-
CP measures during the study (range 1-11). Over 90% of patients 
completed all items at each encounter; missing items (skipped 
by the patient) ranged from 0.5% (bowel function) to 9.5% (sexual 
function). Only eight patients (2.8%) felt that EPIC-CP did not 
enhance communication, and only 15 (5%) felt that the sexual 
function questions were not important to include. Thematic 
analysis of clinicians’ perspectives revealed that EPIC-CP 
captured essential prostate-specific effects, enhanced person-
centred communication, and facilitated customization of 
interventions thus enhancing person-centred care. EPIC-CP and 
ESAS-R showed comparable sensitivity in detecting vitality and 
depression issues in this patient population. 
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Conclusions: EPIC-CP was highly endorsed from healthcare 
practitioners and prostate patients across participating cancer 
centres. The EPIC-CP tool captures prostate-specific symptom 
information that assists in enhancing clinical care and symptom 
management. Provincial roll-out of EPIC-CP as a standard of care 
for PROs in clinical practice is recommended. 
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Purpose: To determine the preferences of radiation oncologists 
in Canada for treatment of low-risk and intermediate-risk 
prostate cancer in an era when no “gold standard” has been 
defined. 
Methods and Materials: A 20-item email questionnaire was sent 
to all practising radiation oncologist in Canada. Responses were 
collected over a four-week interval and are reported 
anonymously as aggregate. 
Results: Thirty-three responses were collected from 10 
provinces. All but two respondents treated prostate cancer 
routinely and saw between six and 30 new patients per month. 
Seventeen out of 31 (55%) prostate cancer treating respondents 
indicated they recommended active surveillance (AS) more 
frequently now compared to five years ago, whereas eight (26%) 
have not made a change in practice. Twenty-two (68%) 
respondents cited the Klotz criteria (PSA ≤ 10ng/mL, Gleason 
score of ≤ 6 or age ≥ 70 years and PSA ≤ 15 and Gleason score of 
≤ 3 + 4) or patient preference as reasons for offering AS. Twenty-
five (81%) would first recommend AS for low-risk prostate cancer. 
Almost all respondents would take the patient off AS for disease 
progression of any type (pathologic, clinical, or biochemical) or 
if the patient decided for treatment with no progression of 
disease. Twenty-two (69%) felt radical prostatectomy (RP) and 
brachytherapy (BT) were equivalent. Two (6%) felt cure rates 
were better with RP and eight (25%) felt BT cure rates were 
better. Eighteen (56%) of respondents would only recommend BT 
to patients with intermediate-risk prostate cancer; nine (28%) 
would outline options of BT, RP and external beam radiotherapy 
(EBRT). If BT was not a treatment option, then 18 (56%) 
respondents would support RP over EBRT. 
Conclusions: This survey confirmed that AS is more strongly 
favoured across Canada by radiation oncologists who treat low 
and select intermediate-risk prostate cancer. BT and RP continue 
to be the preferred recommendations. There was a bias towards 
belief that BT cure rates are better despite the lack of 
randomized evidence. EBRT is felt by most to be less curative 
than either RP or BT. 
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Purpose: To determine the maximum tolerated dose (MTD) of 5 
fraction stereotactic radiosurgery (SRS) delivered with 
concurrent and adjuvant temozolomide (TMZ) in newly diagnosed 
glioblastoma multiforme (GBM).  
Methods and Materials: Adult patients with newly diagnosed 
GBM were treated with escalating doses of SRS in a 3+3 design on 
4 dose levels: 25 Gy, 30 Gy, 35 Gy, and 40 Gy targeting the 
cavity/residual tumour with a 5 mm CTV margin and 0 mm PTV. 
There were 2 arms per PTV size: < 60 cm3 (Arm 1) and 60-150 cm3 
(Arm 2). A dose limiting toxicity (DLT) was defined as CTCAE 
Grade 3-5 CNS toxicity within 30 days of SRS, with life-long 
assessment for late SRS-related adverse radiation effect (ARE). 
The maximum tolerated dose (MTD) was the highest dose where 
0-1 out of six had an acute or late CNS Grade 3-5 toxicity. 
Secondary endpoints included progression free survival (PFS) and 
overall survival (OS). Given the difficulty in interpreting post-SRS 
imaging, any new enhancement was scored as: 1) tumour 
progression, if ultimately determined to be recurrent tumour 
(PD); 2) transient ARE if occurred within five months and 
resolved (i.e., pseudoprogression, PP); 3) persistent ARE (i.e., 
radionecrosis, RN). All AREs were scored per CTCAE.  
Results: From 2010 to 2015, 30 total patients were enrolled. The 
median age was 66 with median KPS of 80. The median GTV was 
26.8 cc (range 3.8–81.0 cc) with a PTV of 60.2 cc (range 14.7–
137.3). Protocol defined DLTs occurred in 2 patients: one 
admitted for PD at 3 weeks (Grade 4, Arm 2, Dose 40 Gy); another 
patient died 1.5 weeks post-SRS from suspected post-operative 
complications (Grade 5, Arm 1, Dose 40 Gy). AREs occurred in 11 
patients: five cases of PP occurring at a median time of 2.8 
months from SRS (range 0.8-3.4); 6 cases of RN (Grade 1 n = 2, 
Grade 2 n = 4) at 6.9 months (range 3.2–12.6). All patients with 
PP and all but one with RN had MGMT methylated tumours. 
Extent of resection (HR 0.19) and MGMT methylation (HR 0.36) 
were associated with improved OS on multivariate analysis. RN 
was not associated with increase in dose, GTV or PTV volume. 
Ultimately, 25 (83%) of patients were treated with bevacizumab, 
started in 17% for symptomatic transient ARE, 6% for persistent 
ARE, and 60% for PD. With a median follow up of 12.9 months, 
the median OS for all patients was 15.0 months, with a median 
PFS of 6.37 months. Median OS was 20.0 months for patients with 
MGMT methylated tumours, versus 11.3 months for MGMT 
unmethylated (p = 0.046). Presence of RN was associated with 
improved median OS (33.2 versus 11.3 months; p = 0.024). 
Amongst MGMT methylated patients who developed RN, median 
OS was 33.5 versus 16.9 months for those without RN (p = 0.10).  
Conclusions: The primary endpoint of dose escalation to 40 Gy 
was achieved without severe treatment-related toxicity. 
However, a dose recommendation based on tumour size cannot 
be made. These results suggest that SRS with concurrent TMZ 
constitutes a safe and feasible treatment for GBM with OS 
comparable to conventional fractionation. 
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Purpose: To assess adequacy of a Foley catheter for urethral 
delineation for evaluation of urethral dose in high-dose rate 
prostate brachytherapy(HDR-PB). 
Methods and Materials: Twenty-one sets of prostate ultrasound 
images were recorded with and without a Foley catheter in 
place. The first images were obtained during HDR-PB for 
intraoperative planning with a Foley catheter in-situ. A standard 
6mm-diameter circle was used to delineate the catheter on 
transverse images, assuming that it represented the urethra. 
Dosimetric optimization parameters were Prostate V100%≥98%, 
V125%: 55-62% and D90% ≥ 100% and urethral V115% = 0 cc. After 
treatment, another set of images was recorded after removing 
the catheter and instilling aerated gel into the urethra without 
removing the brachytherapy needles or changing the patient’s 
position. The images were fused using either Vitesse3.0 or 
BrachyVision11.0. Urethral dosimetric parameters, position and 
volume of the urethra were compared. Paired Student’s t-tests 
were performed for statistical analysis. 
Results: Images were recorded on 16 intermediate to high-risk 
prostate cancer patients who received HDR-PB boost combined 
with 46 Gy/23 fractions external beam radiotherapy. Eight had 
two fractions of 10 Gy in separate implants and the remaining 
eight received 15 Gy in one fraction. Twenty-one paired sets of 
